Please assess the completion status of the following clinical trial:

Trial Title: HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Age 2 months to \< 11 years~2. Confirmed HIV diagnosis. i. Children \> 18 months: Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Western blot, or rapid HIV antibody test ii. Children \< 18 months: Documentation will be DNA PCR confirmation only along with documentation of testing from the referral entity~3. ART-naïve patients eligible for ART initiation per WHO/Uganda guidelines (see Table 1) or Patients receiving first line ART regimen with NNRTI +2 NRTI with at least one HIV RNA \<400 copies/ml within the past 6 months~4. Agreement to come to the study clinic for any febrile episode or other illness~5. Agreement to avoid medications administered outside study protocol~6. Provision of informed consent by parent/guardian and agreement to have child's care at the clinical site~7. Lives within 50 km of study site~Exclusion criteria:~1. ART-naïve children: children or their mothers that have received any dose of Nevirapine in the past 24 months~2. Active medical problem requiring in-patient evaluation at the time of screening or enrollment~3. History of cardiac conduction disorder or known significant cardiac structural defect~4. Children receiving any disallowed medications (see section 4.3)~5. Moderate, Severe or Life-threatening (Grade 2, 3, or 4) AST or ALT found within 4 weeks prior to enrollment:~   * AST: \>113U/L (\>2.5xULN)~  * ALT: \>113U/L (\>2.5xULN)~6. Life-threatening (Grade 4) screening laboratory value found within 4 weeks prior to enrollment for the following:~   * Absolute neutrophil count: \<500 mm3~  * Hemoglobin: \<6.5 g/dL~  * Creatinine: \>3.5xULN~  * Platelets: \<25,000/mm3

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- Lopinavir/ritonavir (LPV/r) +2 NRTI (Type: ACTIVE_COMPARATOR): Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
- Nevirapine (NVP) or Efavirenz (EFV) +2 NRTI (Type: ACTIVE_COMPARATOR): Nevirapine (NVP) or Efavirenz (EFV) +2 nucleoside reverse transcriptase inhibitor (NRTI)

Based on this trial design, predict the completion outcome and termination type (if applicable).